SPRAVATO Antidepressant Treatment

Depression is a chronic mental health condition affecting approximately 1 in every 6 adults. An estimated 16 million American adults struggle with depression every year. The standard of care for depression is treatment with antidepressant medications, such as fluoxetine or citalopram.

However, in some cases, depression symptoms do not improve with antidepressant treatment. Persons who continue to experience symptoms of depression after trying at least two separate antidepressant medications at an appropriate dose for the recommended period of time may be considered to have Treatment Resistant Depression (TRD). In many cases, these individuals will have tried multiple oral antidepressants with little to no relief in their symptoms.

In 2019, the FDA approved a new type of antidepressant medication for the treatment of TRD — SPRAVATO™ (esketamine). Memorial Healthcare System’s Esketamine Clinic is the first certified esketamine treatment center in South Florida.

What is SPRAVATO™ (Esketamine)?

Esketamine is an FDA-approved nasal spray medication approved for treatment of TRD and/or Major Depressive Disorder (MDD) with Suicidal Ideation (SI). Esketamine has been proven to reduce depression symptoms in patients with TRD, when used in combination with oral antidepressant therapy. Esketamine has the potential for dependence and/or addiction and therefore may not be appropriate in patients with a history of substance use disorder(s).

Patients must be referred to our Esketamine Clinic by their outpatient psychiatrist. Treatments are appointment-based and there is no walk-in availability.

Location